Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirelizumab (PD-1 antibody) plus anlotinib in second-line treatment of advanced urothelial carcinoma
ChiCTR2100045112Phase 2Recruiting
- Sponsor
- The Affiliated Hospital of Yanbian University
- Start
- Apr 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab and anlotinib in transitional cell carcinoma (TCC), sponsored by The Affiliated Hospital of Yanbian University. Primary endpoints: Objective response rate, Disease-free survival and 4 more. Started Apr 2021; status: recruiting.
02
Drugs
tislelizumabanlotinib
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on ChiCTR2100045112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045112.